A Sheffield-based aquaculture biotechnology company says it has been through a “transformational” year after selling one of its key divisions for £260m in an effort to simplify its business model.

Though M&A deal value and volume both declined in biopharma in 2024 compared to the year prior, PwC analysts still believe ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Catalent (CTLT) stock rises on reports of imminent $16.5 billion sale to Novo Holdings with FTC approval and EU Commission ...

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.

New York-based Citi is in the midst of a restructuring to focus on the firm’s key businesses, which it identified as trading, ...

Economic resilience and several strong sector showings boost Nordic dealmaking in 2024, with a healthy M&A pipeline for 2025 - ...

In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...

The BIOSECURE Act, which would restrict drugmakers from using key Chinese contract manufacturers, was left out of a defense ...

Catalent, Inc. (“Catalent”) and Novo Holdings A/S (“Novo Holdings”) jointly announced today the unconditional approval granted by the European Commission (EC) for the pending acquisition transaction ...

Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free ...

Recent developments in the health sector include Novo Holdings receiving EU clearance for a $16.5 billion acquisition, US ...